

# Alexander R Lyon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1449937/publications.pdf>

Version: 2024-02-01

144  
papers

20,068  
citations

20817

60  
h-index

11939

134  
g-index

145  
all docs

145  
docs citations

145  
times ranked

19613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
2	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	2.2	1,996
3	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. <i>European Heart Journal</i> , 2018, 39, 2032-2046.	2.2	972
4	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	7.1	920
5	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 8-27.	7.1	835
6	Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 22-29.	3.3	694
7	High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a $\beta_2$ -Adrenergic Receptor/G-protein-Dependent Manner. <i>Circulation</i> , 2012, 126, 697-706.	1.6	625
8	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
9	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. <i>European Heart Journal</i> , 2018, 39, 2047-2062.	2.2	521
10	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , The, 2018, 19, e447-e458.	10.7	376
11	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	13.7	373
12	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the European Society of Cardiology in collaboration with the International Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020,	7.1	364
13	Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6854-6859.	7.1	334
14	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
15	Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. <i>Lancet</i> , The, 2019, 394, 1041-1054.	13.7	294
16	Epidemiology and pathophysiology of Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 387-397.	13.7	283
17	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
18	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239

#	ARTICLE	IF	CITATIONS
19	Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	7.1	234
20	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018, 138, 678-691.	1.6	229
21	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	7.1	224
22	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
23	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
24	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	2.2	212
25	Cardio-Oncology Services: rationale, organization, and implementation. <i>European Heart Journal</i> , 2019, 40, 1756-1763.	2.2	195
26	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
27	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
28	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	7.1	184
29	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	7.1	182
30	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	2.8	179
31	A conducting polymer with enhanced electronic stability applied in cardiac models. <i>Science Advances</i> , 2016, 2, e1601007.	10.3	173
32	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
33	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020, 41, 1720-1729.	2.2	154
34	SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 362-372.	4.8	147
35	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
36	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	7.1	138

#	ARTICLE	IF	CITATIONS
37	Takotsubo syndrome: aetiology, presentation and treatment. <i>Heart</i> , 2017, 103, 1461-1469.	2.9	136
38	Pathophysiology of Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 77, 902-921.	2.8	125
39	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.2	123
40	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.1	115
41	Activity and outcomes of a cardio-oncology service in the United Kingdom—a five-year experience. <i>European Journal of Heart Failure</i> , 2018, 20, 1721-1731.	7.1	105
42	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 854-871.	7.1	105
43	Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 67, 38-48.	1.9	103
44	Plasticity of Surface Structures and $\beta_2$ -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 357-365.	3.9	102
45	Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. <i>Cardiovascular Research</i> , 2017, 113, 1743-1752.	3.8	102
46	Microdomain-Specific Modulation of L-Type Calcium Channels Leads to Triggered Ventricular Arrhythmia in Heart Failure. <i>Circulation Research</i> , 2016, 119, 944-955.	4.5	101
47	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
48	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in $\beta_2$ -adrenergic signaling and enhances apoptosis. <i>Cell Death and Disease</i> , 2015, 6, e1754-e1754.	6.3	98
49	Standard and Advanced Echocardiography in Takotsubo (Stress) Cardiomyopathy: Clinical and Prognostic Implications. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 57-74.	2.8	97
50	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	2.8	97
51	Gene therapy: targeting the myocardium. <i>Heart</i> , 2008, 94, 89-99.	2.9	94
52	The Role of Biomarkers in Cardio-Oncology. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 431-450.	2.4	92
53	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <a href="#">Translational Research Committee</a> of the <a href="#">Heart Failure Association</a> ( <a href="#">HFA</a> ) of the <a href="#">European Society of Cardiology</a> ( <a href="#">ESC</a> ). <i>European Journal of Heart Failure</i> . 2020, 22, 2272-2289.	7.1	92
54	Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. <i>BMJ: British Medical Journal</i> , 2018, 363, k3845.	2.3	91

#	ARTICLE	IF	CITATIONS
55	Gut microbial degradation of organophosphate insecticides induces glucose intolerance via gluconeogenesis. <i>Genome Biology</i> , 2017, 18, 8.	8.8	88
56	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	4.0	80
57	Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 55.	0.9	69
58	Cardiac contractility modulation therapy in advanced systolic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 584-598.	13.7	67
59	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018, 2, 1633-1644.	5.2	66
60	Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 68-79.	4.0	66
61	Heart Failure Association of the European Society of Cardiology update on sodium-glucose cotransporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
62	Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2016, 18, 703-712.	7.1	62
63	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
64	Microtubule-Dependent Mitochondria Alignment Regulates Calcium Release in Response to Nanomechanical Stimulus in Heart Myocytes. <i>Cell Reports</i> , 2016, 14, 140-151.	6.4	55
65	T-tubule remodelling disturbs localized $\beta_2$ -adrenergic signalling in rat ventricular myocytes during the progression of heart failure. <i>Cardiovascular Research</i> , 2017, 113, 770-782.	3.8	53
66	Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in $\beta_2$ AR-cAMP Responsiveness in Murine Hearts. <i>Cell Reports</i> , 2018, 23, 459-469.	6.4	51
67	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	3.8	51
68	Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials. <i>Hypertension</i> , 2015, 65, 401-406.	2.7	44
69	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.9	42
70	Diagnostic criteria for takotsubo syndrome: A call for consensus. <i>International Journal of Cardiology</i> , 2014, 176, 274-276.	1.7	41
71	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. <i>Heart Failure Reviews</i> , 2019, 24, 915-925.	3.9	39
72	Cardiovascular changes during peanut-induced allergic reactions in human subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 633-642.	2.9	37

#	ARTICLE	IF	CITATIONS
73	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.1	37
74	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€”Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 947-959.	1.0	37
75	Pathophysiology of Takotsubo Syndrome. <i>Circulation Journal</i> , 2014, 78, 1550-1558.	1.6	36
76	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
77	Pathophysiology of <sc>T</sc>akotsubo syndromeâ€”A joint scientific statement from the Heart Failure Association <sc>T</sc>akotsubo Syndrome Study Group and Myocardial Function Working Group of the <sc>E</sc>uropean Society of Cardiologyâ€”Part 1: overview and the central role for catecholamines and sympathetic nervous system. <i>European Journal of Heart Failure</i> . 2022. 24. 257-273.	7.1	36
78	Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device â€” the SERCA-LVAD TRIAL. <i>Gene Therapy</i> , 2020, 27, 579-590.	4.5	35
79	Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 149-163.	2.5	35
80	Recent advances in cardioâ€”oncology: a report from the â€”Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019â€”™. <i>ESC Heart Failure</i> , 2019, 6, 1140-1148.	3.1	34
81	Pathophysiology of Takotsubo syndromeAe” a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiologyâ€”Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. <i>European Journal of Heart Failure</i> , 2022, 24, 274-286.	7.1	34
82	The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. <i>Human Gene Therapy</i> , 2015, 26, 293-304.	2.7	33
83	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 611-621.	1.8	33
84	Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. <i>BMC Cancer</i> , 2016, 16, 912.	2.6	30
85	Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. <i>Cardiovascular Research</i> , 2022, 118, 1758-1770.	3.8	30
86	Cardiac Atrophy and Heart Failure In Cancer. <i>Cardiac Failure Review</i> , 2017, 03, 62.	3.0	29
87	Cardioâ€”oncology care in the era of the coronavirus disease 2019 (COVIDâ€”19) pandemic: An International Cardioâ€”Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	329.8	29
88	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. <i>Journal of Cardiac Failure</i> , 2021, 27, 727-743.	1.7	29
89	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2020, 317, 167-173.	1.7	25
90	Computational modeling of Takotsubo cardiomyopathy: effect of spatially varying $\beta$ -adrenergic stimulation in the rat left ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H1487-H1496.	3.2	24

#	ARTICLE	IF	CITATIONS
91	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. <i>Circulation: Heart Failure</i> , 2021, 14, e008209.	3.9	24
92	Short- and Long-Term Clinical Outcomes for Patients With Takotsubo Syndrome and Patients With Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017290.	3.7	24
93	Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts. <i>Cardiovascular Research</i> , 2015, 105, 31-43.	3.8	23
94	Heart failure with preserved ejection fraction. <i>Clinical Medicine</i> , 2018, 18, s24-s29.	1.9	23
95	Modern-day cardio-oncology: a report from the Heart Failure and World Congress on Acute Heart Failure 2018™. <i>ESC Heart Failure</i> , 2018, 5, 1083-1091.	3.1	23
96	Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. <i>Heart</i> , 2021, 107, 1327-1335.	2.9	23
97	Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?. <i>JACC: CardioOncology</i> , 2022, 4, 113-123.	4.0	23
98	Cardio-oncology: Concepts and practice. <i>Indian Heart Journal</i> , 2016, 68, S77-S85.	0.5	20
99	Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. <i>Current Oncology Reports</i> , 2019, 21, 45.	4.0	20
100	Proteasome Inhibitors as a Potential Cause of Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 289-295.	2.1	19
101	Late onset heart failure after childhood chemotherapy. <i>European Heart Journal</i> , 2019, 40, 798-800.	2.2	18
102	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	7.1	17
103	Heart failure resulting from cancer treatment: still serious but an opportunity for prevention. <i>Heart</i> , 2019, 105, 6-8.	2.9	16
104	The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 90-94.	3.0	15
105	Monitoring the heart during cancer therapy. <i>European Heart Journal Supplements</i> , 2019, 21, M44-M49.	0.1	14
106	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	1.4	14
107	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.2	14
108	Takotsubo syndrome in Heart Failure and World Congress on Acute Heart Failure 2019: highlights from the experts. <i>ESC Heart Failure</i> , 2020, 7, 400-406.	3.1	13

#	ARTICLE	IF	CITATIONS
109	Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. <i>Current Heart Failure Reports</i> , 2020, 17, 397-408.	3.3	12
110	Stressing the Importance of Cardiac Assessment in Pheochromocytoma. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2375-2377.	2.8	11
111	Chronic intake of 4-Methylimidazole induces Hyperinsulinemia and Hypoglycaemia via Pancreatic Beta Cell Hyperplasia and Glucose Dyshomeostasis. <i>Scientific Reports</i> , 2018, 8, 17037.	3.3	9
112	Cardiovascular disease following breast cancer treatment: can we predict who will be affected?. <i>European Heart Journal</i> , 2019, 40, 3921-3923.	2.2	9
113	Cardiovascular events in cancer survivors. <i>Seminars in Oncology</i> , 2019, 46, 426-432.	2.2	8
114	Gene Therapy for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2014, 129, 2633-2635.	1.6	7
115	A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H465-H475.	3.2	7
116	Effects of renal denervation on vascular remodelling in patients with heart failure and preserved ejection fraction: A randomised control trial. <i>JRSM Cardiovascular Disease</i> , 2017, 6, 204800401769098.	0.7	7
117	Is P2Y12 inhibitor therapy associated with an increased risk of cancer?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 100-104.	3.0	7
118	Cardiotoxicity Following Cancer Treatment. <i>Ulster Medical Journal</i> , 2017, 86, 3-9.	0.2	7
119	Authors' response to "Stress (Takotsubo) cardiomyopathy" a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, E2-E2.	3.3	6
120	Use of cardiac MRI to diagnose Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 669-669.	13.7	6
121	Cardio-oncology: rationale, aims and future directions. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 134-140.	1.3	6
122	Cardio-oncology for the general cardiologist. <i>Heart</i> , 2021, 107, 1254-1266.	2.9	6
123	Gene therapy for GM1 gangliosidosis: challenges of translational medicine. <i>Annals of Translational Medicine</i> , 2015, 3, S28.	1.7	6
124	The year in cardiovascular medicine 2021: cardio-oncology. <i>European Heart Journal</i> , 2022, , .	2.2	6
125	The effect of head-up tilt upon markers of heart rate variability in patients with atrial fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12511.	1.1	5
126	What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. <i>Clinical Oncology</i> , 2021, 33, 483-493.	1.4	5



#	ARTICLE	IF	CITATIONS
127	An integrated approach to cardioprotection in lymphomas. <i>Lancet Haematology</i> , 2022, 9, e445-e454.	4.6	5
128	A cross-sectional imaging study to identify organs at risk of thermal injury during renal artery sympathetic denervation. <i>International Journal of Cardiology</i> , 2015, 197, 235-240.	1.7	4
129	Challenges of Chronic Cardiac Problems in Survivors of Takotsubo Syndrome. <i>Heart Failure Clinics</i> , 2016, 12, 551-557.	2.1	4
130	Device closure for patent foramen ovale in patients with cryptogenic stroke: which patients should get it?. <i>European Heart Journal Supplements</i> , 2020, 22, M43-M50.	0.1	3
131	Takotsubo cardiomyopathy. <i>British Journal of Hospital Medicine (London, England)</i> , 2013, 74, 96-103.	0.5	2
132	Break a sweat to reduce cardiotoxicity – the benefits of exercise training during anthracycline chemotherapy. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 301-304.	1.8	2
133	CMR unveiling the cause of post CoVid-19 infection chest pain. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2025-2026.	1.5	2
134	Cardiac Stem Cell Therapy and Arrhythmogenicity: Prometheus and the arrows of Apollo and Artemis. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 207-216.	2.4	1
135	Microcirculatory dysfunction and autonomic disturbance in Takotsubo syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 497-497.	13.7	1
136	Bubbles in Ballooning: Safety and Utility. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 845.	2.8	1
137	Irreversible apical ballooning may also occur. <i>British Journal of Hospital Medicine (London, England)</i> , 2015, 78, 1431-1434.	0.5	0
138	Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous takotsubo syndrome – insights from exercise echocardiography. <i>European Heart Journal</i> , 2019, 40, 1917-1924.		0
139	Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous Takotsubo syndrome - Insights from exercise echocardiography. <i>European Heart Journal</i> , 2019, 40, 1917-1924.	2.2	0
140	Cancer and cardiovascular disease – Authors' reply. <i>Lancet</i> , 2020, 395, 1904-1905.	13.7	0
141	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e21516-e21516.	1.6	0
142	Risk of hypertension (HTN) and malignant hypertension (mHTN) in patients treated for multiple myeloma (MM). <i>Journal of Clinical Oncology</i> , 2016, 34, 8049-8049.	1.6	0
143	The year in cardiology 2019: heart failure. <i>Revista Romana De Cardiologie</i> , 2020, 30, 185-204.	0.1	0
144	Ventricular arrhythmias in patients with immune checkpoint inhibitor myocarditis. <i>European Heart Journal</i> , 2021, 42, 1717-1724.	2.2	0